Paratek clears one last big hurdle on the way to an FDA marketing decision for antibiotic

Paratek’s $PRTK antibiotic omadacycline went three for three in Phase III. And now it looks ready to move on to a near-term FDA approval.

An agency expert panel provided its blessing for a marketing approval on Wednesday, voting 17-to-1 to recommend it for acute bacterial skin and skin structure infections with a still-lopsided 14-to-4 vote favoring an OK for community-acquired bacterial pneumonia.